News details

Idorsia announces the results of REACT a Phase 3 study of clazosentan in patients following aneurysmal subarachnoid hemorrhage

Idorsia submits European marketing authorisation application for aprocitentan for the treatment of patients with resistant hypertension

Idorsia presents at the 41st J.P. Morgan Healthcare Conference – Achievements in 2022 provide the foundation for our success in 2023

Idorsia submits a New Drug Application to the US FDA for aprocitentan for the treatment of patients with difficult-to-control hypertension

Idorsia initiates OPUS a Phase 3 program to investigate cenerimod for the treatment of patients with systemic lupus erythematosus

Long-term safety and tolerability results with daridorexant in patients with insomnia disorder published in CNS Drugs

Swissmedic approves QUVIVIQ (daridorexant) – a first-in-class treatment for chronic insomnia disorder to improve both nighttime symptoms and daytime functioning

Idorsia and Simcere enter into a licensing agreement for daridorexant in China

QUVIVIQ (daridorexant) – Europe’s first dual orexin receptor antagonist – is now available for patients with chronic insomnia disorder in Italy and Germany

Idorsia congratulates its Chief Scientific Officer Martine Clozel who has been honored by Initiative Switzerland with the Annual Prix Suisse Award

The Lancet and AHA late-breaking science session reports significant and sustained effect of aprocitentan on lowering blood pressure for patients with resistant hypertension

Idorsia announces financial results for the first nine months of 2022 – QUVIVIQ becoming a global brand

Idorsia Japan announces positive results with daridorexant in a Phase 3 study of Japanese patients with insomnia

Idorsia secures additional cash by entering into a building sale and leaseback agreement

Idorsia announces financial results for the first half 2022 – reaching commercial stage

Positive Phase 3 study with aprocitentan demonstrates significant antihypertensive efficacy in patients with resistant hypertension

Phase 2a study results in binge eating disorder

Europe’s first dual orexin receptor antagonist – QUVIVIQ (daridorexant) – granted approval to improve both nighttime symptoms and daytime functioning in adults with chronic insomnia disorder

Idorsia’s new treatment QUVIVIQ (daridorexant) is now available in the US for adults living with insomnia

Idorsia announces financial results for the first quarter 2022 – first product launched, second in the starting blocks